International Clinical Trial: Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2051260092) titled 'Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)' on June 24.

Study Type: Interventional

Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

Primary Sponsor: Medical Affairs

Condition: Symptomatic Hypertrophic Cardiomyopathy

Intervention: Experimental Arm - Aficamten tablets administered orally. - Patients take daily dose of aficamten (5 to 20 mg). Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose....

Recruitment Stat...